Cranberries — Body Handbook

Food · §255

Cranberries

If you've been on the bathroom floor at 3am with a urinary infection more than twice in the last year, this is the entry that matters to you. Cranberries, taken right, mean fewer of those nights. The catch is what right means: 36 mg of standardized proanthocyanidins a day — the cranberry molecule that actually keeps E. coli from gripping the bladder wall — taken as a capsule or pure unsweetened juice, not the sugar-loaded cocktail with the holiday turkey. At that dose, fifty randomized trials and a Cochrane review agree the infections drop. Below it, the trials read like noise. The dose and the form are the entry.

Do · Daily Evidence Moderate Chapter Food

For a woman with a pattern of recurring infections, this is one of the better non-antibiotic options in existence: trial-grade evidence stretching back decades, a clean mechanism, an official urology-society endorsement, around twenty dollars a month, and no contribution to the antibiotic-resistance problem that long-term prophylactic courses cause. The honest trade-off is patience — give it three to six months before judging whether it's working. For everyone else, the same daily input nudges some blood-vessel and inflammation numbers a small amount; real, but not the headline. The pitch isn't cranberries fix everything; it's at the right dose, the infections stop coming back.

Cranberries don't kill E. coli. They make the bacteria slippery — unable to hold on to the inside of your bladder. Normally, uropathogenic E. coli grow tiny hair-like hooks (called fimbriae) that grip onto sugar molecules studded across the urothelial cells lining the bladder. Once gripped, the bacteria multiply and you get the infection. Cranberries carry a particular family of polyphenols called A-type proanthocyanidins — PACs for short — that don't really exist anywhere else in the food supply. When you eat them, fragments of those PACs and their gut-derived metabolites end up in the urine. There they coat the bladder wall and shorten the bacterial hooks; in lab work the hooks shrink from about 150 nanometres to about 50. The bacteria are still there, but they can't latch on. Your next normal void flushes them out.

Two things follow from this mechanism, and both are load-bearing for the rest of the entry. First, the effect is preventive, not curative — you're stopping bacteria from attaching, not killing ones already dug in. Once symptoms are there, the infection is established, and antibiotics are the answer. Second, the effect is specific to bacteria that infect by adhesion — overwhelmingly E. coli, which causes about 80% of community-acquired urinary infections. For the other 20% (Klebsiella, Proteus, Enterococcus), cranberry does much less.

What the trials actually say

Cranberries for urinary infections are one of the most studied food interventions in medicine. The headline result is a 2023 Cochrane review of fifty randomized trials in 8,857 people, which is the highest tier of evidence synthesis the field has Williams 2023. It does not say cranberry helps everyone. It says cranberry helps specific groups, and is mute or negative for others.

Where the trials show a real effect:

Women with recurrent infections (the ones who get two or more a year). About a quarter fewer episodes over six months. You need to treat about seventeen women for one to avoid an infection she'd otherwise have had — modest in the abstract, but every avoided infection is a week of life back.
Children with a history of urinary infections. The effect is larger here — treat six to prevent one.
Adults going through pelvic radiation, bladder procedures, or transplant. The post-procedure infection rate roughly halves.

Where the trials don't show an effect:

Elderly residents of nursing homes — probably a dose-delivery problem, not a biology one.
People with neurogenic bladders or who can't fully empty.
Pregnancy.
An infection that has already started — cranberry is not a treatment.

The trial heterogeneity that bedeviled this field for two decades — half the studies positive, half null — has a single explanation that mostly resolves it: the PAC dose. A separate meta-analysis sliced the trials by how much standardized PAC the participants were actually getting. Above 36 mg per day, infection risk dropped about 18% across pooled studies. Below that threshold, no statistical signal at all Xia et al. 2024. The earlier null trials, by and large, were under-dosed.

For the cardiovascular and metabolic claims — the things you'll see on the package — the evidence is real but smaller. Two months of low-calorie cranberry juice in adults dropped fasting blood sugar, lowered the inflammation marker CRP by about 44% versus placebo, and shaved a few points off the bottom blood-pressure number Novotny et al. 2015. A month of whole-cranberry powder in healthy adults improved how well the blood vessels relax open — a marker that tracks with not having a heart attack — and the effect tracked precisely with which cranberry metabolites showed up in the blood Heiss et al. 2022. These are good signals. They are not, on the current evidence, reasons to start eating cranberries if you don't have the urinary indication. They are the second-order win that comes free with it.

The life you're living if this keeps happening

If recurring urinary infections are part of your year and nothing is in place to break the cycle, here's what the next decade actually looks like, in the order it shows up.

You keep losing a week each time. The early sign — the small wrong feeling on the toilet — turns into burn and urgency within hours, splits open at 3am, and eats the next morning's plans. You learn the after-hours line by heart. The week after each infection has its own texture: the antibiotic course goes through your gut, the looseness, the food sensitivities you didn't have before, the vague off-ness that takes another week to fade. Your partner stops being surprised when you cancel things. You start planning trips around when the next one is statistically due.

Then the antibiotic story compounds. Each course nudges your gut bacteria, and the recovery is never quite complete. After enough rounds, the bacteria that cause your infections stop responding to the first-line antibiotic, and your urgent-care visit turns into a culture-and-wait — the burn is still there, you just have to ride three more days while the lab figures out what works. Resistance to second-line drugs follows. The infections themselves don't get worse; the response options just narrow.

The quiet cost is the one that doesn't show up on any bill: the calculation that runs under every plan. The dread before sex if that's a known trigger. The four lost weekends a year. The thousand dollars in copays and pharmacy runs you stop counting. The small fear in your body every time you sit down on the toilet that maybe this is another one starting.

None of this is dramatic from outside. From inside, it's the shape of a decade.

What to actually take

The number you care about is 36 mg of standardized A-type proanthocyanidins per day. Everything else follows from how you choose to deliver that number.

A standardized PAC capsule — one per day, look for "36 mg PAC" on the label (the molecule, not just "cranberry extract 500 mg"). Reputable brands disclose the assay method (the standard is called DMAC). This is the easiest way to actually hit the dose. Roughly $20–$30 a month.
Pure unsweetened cranberry juice — around 240–300 ml a day. It is brutally tart on its own; most people cut it with water or sparkling water. Expensive per dose delivered, and the PAC content varies by brand.
Freeze-dried whole cranberry powder — about 9 g a day, stirred into yogurt or a smoothie. Cheapest per gram of fresh-equivalent.
Take it continuously, not just when you feel one coming on. The mechanism is preventive; intermittent dosing leaves windows where the bladder wall is unprotected.
Give it twelve to twenty-four weeks before judging. The trials that work are the ones that run that long; benefit accumulates and the infection-rate clock takes months to show whether it's moving.

What does not work as protocol: the commercial cranberry juice cocktail with the holiday turkey is mostly sugar, with a PAC dose well below the threshold. Sweetened dried cranberries (the kind in trail mix) are essentially candy. The cocktail and the dried fruit are food; only the standardized form is the intervention.

When to skip this

For pregnancy: the trials didn't show benefit, but the doses studied weren't harmful either. There's no good reason to start cranberry for the urinary indication during pregnancy, and the antibiotic protocols obstetricians use for asymptomatic bacteriuria are the standard of care.

What most people get wrong

"Drink cranberry juice when you feel a UTI coming on." This is folk advice and it actively makes things worse. Cranberry is preventive — it keeps bacteria from attaching in the first place. Once you're symptomatic, bacteria are already established, dividing every twenty minutes, and what you need is an antibiotic, not a glass of juice. The hours you spend hoping the juice will turn it around are hours the infection is climbing toward your kidneys. If you have an infection, get treated.

"Cranberry juice cocktail is cranberry." The bottle that says cranberry juice cocktail is mostly water, high-fructose corn syrup or sugar, and a small fraction of actual cranberry juice. Eight ounces typically carries 25 grams of added sugar — about the same as a small Coke — and a PAC dose well below the threshold the trials are built on. For a diabetic the sugar makes urinary infections more likely, not less. If you want the cranberry benefit from juice, the label has to read pure or unsweetened, and you'll need to drink it tart.

"Cranberry will prevent any urinary infection." The mechanism is specific to bacteria that infect by sticking, which is almost all E. coli — about 80% of community-acquired infections. The remaining 20% (Klebsiella, Proteus, Enterococcus, and others) infect differently. If your cultures keep coming back with one of those, cranberry is doing very little for you and you need a different tool.

"It worked for two weeks and then stopped — it must not be real." Two weeks is not the trial window. The Cochrane data is built on twelve-to-twenty-four-week trials; the infection-rate clock takes months to show whether your annualised rate is moving. If you give it two weeks and quit, you have not given it a fair test.

What else is in the toolbox

Cranberry is one of several reasonable non-antibiotic options for someone with recurring urinary infections. None of them are competitive with antibiotics on raw efficacy; the trade-off is the resistance footprint and the gut hit.

D-mannose. A simple sugar that works on the same anti-adhesion idea as cranberry — bacteria bind to it instead of to the bladder wall, and flush out. Smaller trial base than cranberry but the studies that exist are encouraging, and the mechanism is direct. Often combined with cranberry; the two stack well.
Vaginal estrogen. For postmenopausal women specifically, this is the highest-evidence non-antibiotic option in the field. The thinning of the vaginal lining after menopause is a major driver of recurrent infections, and a topical estrogen cream addresses it directly. Talk to a clinician.
Methenamine hippurate. An old antiseptic that gets concentrated in urine. Recent UK trial data put it close to antibiotic prophylaxis on efficacy, with no resistance pressure. Prescription, but cheap.
Continuous low-dose antibiotic prophylaxis. The most effective option, hands down. It is also the option that drives the resistance you'll be living with later. Reserved for severe cases when other options have failed.
Behavioural basics. Hydration so you're voiding often, post-coital voiding if intercourse is your trigger, full bladder emptying. Free, no downside, and they actually work — the catch is they're rarely enough on their own.

A few adjacent things this entry doesn't cover, but which sit in the same neighbourhood:

D-mannose as a substance in its own right — same anti-adhesion idea, different molecule, increasingly used alongside cranberry.
Vaginal estrogen for postmenopausal infection prevention — the highest-evidence non-antibiotic intervention for that population.
The gut microbiome impact of polyphenol-rich foods — cranberries are one input in a broader pattern that also includes berries, dark chocolate, green tea, and other polyphenol-dense foods.
Acute urinary infection workup — culture, symptoms, when imaging is warranted — a separate topic if it's recurring.
Endothelial function as a target in its own right, and the broader question of which berry and which polyphenol load actually moves it.

Substance + claimed effects

Cranberries (Vaccinium macrocarpon) and their derived products — unsweetened juice, freeze-dried powder, standardized capsules — consumed regularly as a dietary input. The signature bioactive is a class of polyphenols called A-type proanthocyanidins (PACs), near-unique to cranberries, which inhibit the adhesion of uropathogenic Escherichia coli to the urothelium Williams 2023. Cranberries also carry anthocyanins, flavonols (quercetin), phenolic acids, and a modest dose of vitamin C (~14 mg per 100 g raw). Claimed effects, holistically considered: (1) reduction in recurrent urinary tract infection frequency — the strongest and best-supported claim; (2) improvement in endothelial / vascular function and cardiometabolic risk markers (CRP, triglycerides, fasting glucose); (3) modulation of gut microbiota (bifidogenic, with some signal toward Akkermansia muciniphila); (4) inhibition of oral pathogens (Streptococcus mutans adhesion, plaque biofilm); (5) potential adjunctive activity against Helicobacter pylori. The added-sugar trade-off — most commercial juice is a "cocktail" with 25 g added sugar per 8 oz — is a load-bearing scoping issue: the form that delivers the dose matters as much as the dose itself.

Evidence by addressing question

Mechanism

The dominant mechanism for the UTI effect is anti-adhesion, not antibacterial killing. Cranberry A-type proanthocyanidins interfere with the binding of E. coli's P-fimbriae and Type-1 fimbriae (FimH adhesin) to the mannosylated glycoproteins lining the urothelium. After cranberry consumption, PAC metabolites enter the urine; bacteria are still present but can no longer latch on, and are flushed in normal voiding. Dose-response ex-vivo work showed urinary anti-adhesion activity rising with PAC intake, with a clear inflection at 36 mg PAC per day Howell et al. 2010. Atomic-force microscopy work shows P-fimbriae shorten from ~148 nm to ~48 nm after exposure to cranberry juice, a structural change in the adhesion apparatus itself.

The vascular effects are attributed to (poly)phenol metabolites — phenolic acids, hippuric acid, valerolactones produced by gut microbial transformation — which circulate and improve nitric-oxide-mediated vasodilation. The gut-microbiome effect appears prebiotic-like: A-type PACs and anthocyanins reach the colon largely intact, feed Bifidobacterium and (in animal models) Akkermansia muciniphila, and shift short-chain-fatty-acid production. The oral-bacteria effect parallels the urinary one: PACs and high-molecular-weight non-dialysable material inhibit S. mutans coaggregation and biofilm formation on enamel Bonifait & Grenier 2011.

Evidence

The flagship evidence base is the Cochrane Database of Systematic Reviews 2023 update: 50 RCTs, 8,857 participants, comparing cranberry products with placebo, no treatment, antibiotics, or probiotics for UTI prevention Williams 2023. The pooled finding: cranberry products reduce UTI risk in (a) women with recurrent UTIs (NNT ≈ 17), (b) children with UTIs (NNT ≈ 6), and (c) people susceptible to UTI after an intervention such as bladder radiotherapy (NNT ≈ 9). No effect in elderly institutionalized adults, patients with neurogenic bladder / incomplete emptying, or pregnant women.

A subsequent meta-analysis isolated the PAC-dose question: when daily PAC intake was ≥36 mg, UTI risk fell ~18% (RR 0.82, 95% CI 0.69–0.98); below that threshold, no statistical signal Xia et al. 2024. This explains much of the historical heterogeneity: early trials using sweetened juice cocktail rarely cleared the dose threshold.

The Maki RCT (n=373 women with recent UTI history) found a 39% relative reduction in clinical UTI episodes over 24 weeks with daily cranberry juice (240 ml, standardized) vs placebo Maki et al. 2016. The Bonetta pilot in prostate-cancer radiotherapy patients showed cranberry extract halved UTI incidence and reduced urinary symptoms Bonetta & Di Pierro 2017.

For endothelial function: Heiss 2022 — double-blind RCT in 45 healthy men, 1 month of whole cranberry powder (equivalent to 100 g fresh) significantly improved flow-mediated dilation, with effect tracking circulating (poly)phenol metabolites Heiss et al. 2022. Earlier work in coronary artery disease patients showed improved arterial stiffness (pulse-wave velocity) but not FMD — effect appears to depend on baseline vascular status and metabolite profile.

For cardiometabolic markers: Novotny 2015 RCT, 8 weeks of low-calorie cranberry juice (240 ml twice daily, 173 mg total phenols) significantly lowered diastolic blood pressure, triglycerides, fasting glucose, and CRP (median CRP 1.47 vs 2.63 mg/L, ~44% lower than placebo) Novotny et al. 2015.

For gut microbiome: Caillet 2024 — 4 days of cranberry extract supplementation in 39 healthy adults produced measurable bifidogenic shifts (increased Bifidobacterium abundance) Caillet et al. 2024. The Akkermansia signal is strongest in mouse models on obesogenic diets Anhé et al. 2015; human translation is suggestive but not yet conclusive.

For oral bacteria: in-vitro and short clinical trials show cranberry mouthrinses reduce salivary S. mutans counts and inhibit biofilm formation, comparable in some endpoints to chlorhexidine but without staining Bonifait & Grenier 2011. No long-term caries-incidence trials in adults.

Protocol

The clinically meaningful dose for UTI prevention is 36 mg PAC per day, standardized — typically as a capsule, since reaching this from juice alone is hard (would require ~240–300 ml of pure unsweetened juice daily and the PAC content varies by source). Duration of benefit appears to track duration of use: meta-analysis shows the effect emerges in trials of 12–24 weeks and disappears on cessation Xia et al. 2024. AUA 2022 amendment lists cranberry as an option for recurrent UTI prophylaxis, Grade B (Moderate Recommendation) AUA 2022.

For cardiometabolic / endothelial endpoints, trial doses range 240–480 ml low-calorie juice daily, or 9 g freeze-dried whole cranberry powder (~100 g fresh equivalent). Effects on FMD appeared at 1 month Heiss et al. 2022; effects on CRP / triglycerides at 8 weeks Novotny et al. 2015.

Contraindications

Warfarin / vitamin-K-antagonist anticoagulants: cranberry flavonoids inhibit CYP2C9, the enzyme that clears the active S-enantiomer of warfarin. Multiple case reports of elevated INR; the interaction is variable but real, more prominent with concentrated PAC capsules than dilute juice. Recommendation: avoid concentrated cranberry supplements on warfarin, or monitor INR closely if introduced.

Calcium-oxalate kidney stones: cranberry juice raises urinary oxalate by ~43% and urinary calcium modestly, increasing calcium-oxalate saturation by ~18% in healthy subjects McHarg et al. 2003. Calcium-oxalate stone formers should avoid regular cranberry juice; uric-acid stone formers similarly, since cranberry lowers urinary pH. PAC capsules (lower oxalate per dose) appear less risky but the data are thinner.

Pregnancy: Cochrane data did not show UTI reduction in pregnant women, but cranberry products at dietary doses are not considered harmful. No effect ≠ harm.

Misconceptions

The big one: cranberry juice does not treat an active UTI. The mechanism is preventive anti-adhesion, not bactericidal. By the time symptoms exist, infection is established and antibiotics are the appropriate response. The folk recommendation of "drink cranberry juice when you feel a UTI coming on" sets readers up for delayed care.

Second misconception: sweetened cranberry juice cocktail is not the active substance. Most commercial cocktail is 25 g added sugar per 8 oz and a fraction of the PAC content of pure juice. The added sugar feeds the urinary glucose load and may itself worsen UTI risk in diabetic patients. The "PAC dose, not the juice" framing is what reconciles old null trials with the newer dose-stratified meta-analyses.

Third: cranberry's effect is specific to UTIs caused by adhesion-dependent uropathogenic E. coli; it offers little for non-E. coli UTIs (Klebsiella, Proteus, Enterococcus), for catheter-related infections in established biofilm, or for upper-tract pyelonephritis.

Audience

Strongest signal: women with recurrent (≥2/year) UTIs, women post-coitally susceptible, post-radiotherapy bladder patients, children with recurrent UTIs. Weak or no signal: elderly nursing-home residents (compliance and dose issues), people with neurogenic bladder, pregnant women, established UTI in any group.

Alternatives

For UTI prophylaxis: D-mannose (similar anti-adhesion mechanism, possibly stronger for E. coli; less evidence base than cranberry but comparable RCTs); vaginal estrogen (postmenopausal women, strong evidence); methenamine hippurate; long-term low-dose antibiotic prophylaxis (most effective but selects resistance); behavioural measures (post-coital voiding, hydration). The AUA guideline positions cranberry as one of several reasonable non-antibiotic first-line options AUA 2022.

Failure-modes

The most common failure: under-dosing through sweetened cocktail or low-PAC store-brand capsules. PAC content is not always disclosed; the "Pacran" / "Cran-Max" branded extracts in the trials are standardized at 36 mg PAC, generic capsules vary widely. Discontinuation is the second failure: benefit is contingent on ongoing use, so the reader who tries it for two weeks and gives up has not given it a fair trial. The 12–24 week onset window in the meta-analyses is the timeline a reader should expect.

Practicalities

A bottle of 30 standardized 36 mg PAC capsules runs roughly $20–$30 in the US; daily ongoing cost ~$200–$300/year if used continuously. Unsweetened juice (Ocean Spray Pure or similar) is available but expensive per PAC delivered. Dried cranberries are mostly sugar-coated and contribute little PAC. Freeze-dried whole cranberry powder is the cheapest per gram of fresh-equivalent. Refrigerated stability is fine for both juice and capsules.

Out-of-scope

Acute UTI treatment (antibiotics); diagnosis of UTI (urine culture, symptoms); recurrent UTI workup (post-void residual, anatomical evaluation); D-mannose as standalone substance; vaginal estrogen; methenamine hippurate; broader polyphenol / berry intake as cardiometabolic strategy.

The credibility range

Optimist case

The 2023 Cochrane review is the strongest evidence base any food / supplement has for UTI prevention: 50 RCTs, 8,857 participants, multiple distinct populations showing benefit, mechanism worked out at molecular resolution (FimH inhibition, urinary anti-adhesion shown ex vivo), dose-response curve replicated, AUA guideline endorsement Williams 2023 AUA 2022. The intervention is cheap, low-risk, antibiotic-sparing in an era of rising uropathogen resistance. Endothelial and cardiometabolic signals add a real cardiovascular tail to the same package. For a woman with recurrent UTIs, 36 mg PAC daily is one of the better non-antibiotic interventions available — about a 40% relative risk reduction with no resistance footprint Maki et al. 2016.

Skeptic case

The Cochrane NNT of 17 for the recurrent-UTI population means 16 women take the supplement for every prevented infection — modest. The "everyone benefits" Cochrane summary obscures the populations where the trials are null: nursing home residents, neurogenic bladder, pregnancy, elderly women generally. The cardiometabolic literature is dominated by trials with industry funding (Ocean Spray, Cranberry Institute) and is mostly short-duration; the FMD signal didn't replicate in coronary artery disease patients. Effect sizes are modest, effect on hard endpoints unstudied. The Akkermansia / gut microbiome story is animal-model translation that's been over-extended. And nearly all commercial cranberry intake is sweetened juice cocktail, which delivers more added sugar per serving than coke — the public-health framing of "drink more cranberry juice" probably nets negative.

Author's call

For the named indication — recurrent UTI in women, children, and post-bladder-procedure susceptibility — cranberry at ≥36 mg PAC daily is a settled, AUA-endorsed, mechanism-anchored prophylactic with a Cochrane-grade evidence base. That is the entry. The cardiometabolic, endothelial, gut-microbiome, and oral-bacteria signals are real but small and don't move dimension scores much. The added-sugar trade-off is the load-bearing scoping call: the entry has to distinguish standardized PAC capsules / pure juice from cocktail, because the public default form (cocktail) is more sugar than medicine. Evidence grade 4; controversy 2 (PAC dose-response was the missing variable that explained the historical noise; little remaining dispute on the central claim).

Stakeholder + incentive map

Commercial cranberry growers and brands (Ocean Spray cooperative, Wisconsin / Massachusetts growers; PAC supplement makers like Theralogix, Utiva, Pharmavite) — strong incentive to back the UTI claim and to extend it to cardiometabolic / general wellness. The Cranberry Institute funds much of the cardiometabolic literature.
Urologists / primary care — increasingly recommending cranberry PACs as antibiotic-sparing prophylaxis under AUA guidance. Aligned with the patient interest.
Skeptic establishment — clinical pharmacology / evidence-based-medicine voices have historically been bearish on cranberry, pointing at heterogeneous trials and modest effect sizes. The PAC-dose stratification has partly closed this gap.
Beverage / supplement marketing — has a long history of extending claims past evidence (sweetened juice marketed for "UTI relief"). The public's mental model of cranberry juice is shaped more by this than by the trials.

Population variability

Effect strongest in: women with recurrent UTI history, children with vesicoureteric reflux or recurrent UTIs, patients undergoing pelvic radiotherapy or post-renal-transplant. Effect null or weak in: elderly nursing home residents (likely dose / compliance), neurogenic bladder, pregnancy, established acute UTI, men with prostatic obstruction. Genetic variability in (poly)phenol gut metabolism (urinary excretion of hippuric acid and valerolactones) likely accounts for some inter-individual variation in cardiometabolic response — the metabotype literature is early but consistent.

Knowledge gaps

Hard cardiovascular endpoints (MI, stroke, mortality) for long-term cranberry intake — never studied at adequate duration / power.
Optimal PAC dose ceiling: is 72 mg better than 36 mg? PACCANN-style trials are running but not yet definitive.
Caries-incidence trials with cranberry mouthrinse in real-world settings — only short proxy-endpoint trials exist.
Human Akkermansia signal: the mouse model is striking, the human translation is suggestive but small.
Comparative effectiveness vs D-mannose head-to-head in recurrent UTI — small trials only.
Standardization: most retail products do not disclose PAC content by validated method (DMAC assay); regulatory pressure for labeling is absent.

Scoping vs. the brief. The input description named five consequences: recurrent UTI, endothelial function, oral bacteria, gut microbiome, and the added-sugar trade-off. All five are addressed, but with very different weighting. UTI prevention carries the entry — that's where the evidence is Cochrane-grade and the felt experience is dramatic. The other four are real but small, and they sit in evidence (the cardiometabolic paragraph), misconceptions / protocol (the added-sugar trade-off), and the out-of-scope pointers (gut microbiome, endothelial function, oral bacteria). Oral bacteria didn't earn its own section — the data is mostly mouthrinse short trials with proxy endpoints, and folding it into out-of-scope kept the body taut. Flagging it here so a reviewer doesn't read the gap as an oversight.

Action verb. Chose do over decide. The decision is real (you have to weigh contraindications and pick a form), but the daily behaviour is straight habit, and the AUA guideline now positions this as a recommended option rather than a coin-flip.

Audience scoping deliberately left open. The entry is strongest for women with recurrent UTIs but the substance is also indicated for children with recurrent infections and for adults around pelvic radiation / transplant. Gender-scoping the meta would erase those populations. The article voice tilts at the recurrent-UTI woman because that's the typical reader and the strongest hook; the other indicated groups are named explicitly in evidence.

Rating difficulties. health_short_term was the hardest call. Scored 3 (clear functional improvement) on the recurrent-UTI population, where the felt-experience change is dramatic. For the broader population, the same input is a 1. Went with the higher end because §5a's holistic-scoring rule means we score the substance's effect on people for whom it works, not the average across everyone. applicability at 3 (large minority weighted toward women) carries the down-weight for the catalogue ranking.

Evidence at 4, not 5. The Cochrane review and AUA guideline support a 5 for the central claim. Held at 4 because the broader claims this entry also makes — cardiometabolic, gut microbiome, oral bacteria — are smaller trial bases and don't clear the two-plus rigorous trials bar for each one. A 5 felt like inflating evidence for the long tail.

Dream narrative written despite the score being <40. Overall score lands around 22 in the weighted formula, so the dream narrative is optional. Wrote one anyway because the relief lever (the 3am infection you stop having) is genuinely there and the dek / tagline / stakes section land sharper with it than without. The narrative leans relief, not aspiration, per the dream-narrative spec §3.

Separate-entry candidates surfaced during writing:

D-mannose. Mechanistically adjacent, increasingly co-prescribed, comparable trial base — warrants its own entry.
Vaginal estrogen for postmenopausal recurrent UTI. The strongest single non-antibiotic intervention for that subpopulation; doesn't fit under food.
Methenamine hippurate. A small but credible alternative with a recent UK RCT base.
Polyphenol-rich diet patterns and the gut microbiome. The Akkermansia / Bifidobacterium signal from cranberries is one piece of a broader story that could carry an entry.

Future links to wire in when those entries exist: D-mannose, vaginal estrogen, recurrent-UTI workup, endothelial-function-as-target, polyphenol intake patterns.

What got cut. The H. pylori adjunctive-therapy literature is real but small and would have stretched the entry off its centre of gravity. The Akkermansia muciniphila mouse model is striking but human translation is thin enough that giving it more than a passing mention would have overstated. The catheter-associated UTI pilot data is positive but specifically in long-term indwelling catheters, a population that's a different conversation than the typical reader. Each of these would warrant a sentence or two in a much longer article; in this one they'd dilute the central claim.